Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Altimmune Appears To Have A Winner, But Will The Market Believe?
10:19am, Friday, 02'nd Dec 2022
On September 14, shares plummeted 27% on topline results from a Phase 1 study of pemvidutide. Reductions in liver fat appear to be substantially better than that of the two leading drug candidates for
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
03:01pm, Thursday, 01'st Dec 2022 Benzinga
Upgrades
Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55 in the third quarter, compared to $0.43 in the year-ago quarter
My 3 Top Biotech Stock Picks for 2023
01:30pm, Tuesday, 22'nd Nov 2022 The Motley Fool
Biotech stocks are set to shine in 2023.
Altimmune to Participate at Two Upcoming Investor Conferences
07:30am, Tuesday, 22'nd Nov 2022
GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti
4 Analysts Have This to Say About Altimmune
08:30pm, Friday, 11'th Nov 2022 Benzinga
Within the last quarter, Altimmune (NASDAQ:ALT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
0
0
Last 30D
0
Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates
01:15pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
12:00pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022
Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates
09:47am, Thursday, 10'th Nov 2022
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
11:30am, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial r
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
07:30am, Thursday, 03'rd Nov 2022
GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial res
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
11:30am, Friday, 28'th Oct 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming sc
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
07:30am, Friday, 28'th Oct 2022
GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scie
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
11:30am, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023 Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
07:43am, Monday, 26'th Sep 2022 Benzinga
Gainers
Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares climbed 46.4% to close at $0.3750 on Friday.
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
04:16pm, Friday, 23'rd Sep 2022 Benzinga
Gainers
Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day ex
